Delcath Systems, Inc.

388 articles with Delcath Systems, Inc.

• Delcath Systems Schedules Conference Call to Report 2021 Second Quarter Financial Results

  7/28/2021

  Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2021.

• Delcath Systems to Present at Access to Giving Virtual Conference on July 13, 2021 at 3 p.m. ET

  7/7/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced that the company will present at Access to Giving Virtual Conference.

• Delcath Systems Set to Join Russell Microcap® Index

  6/8/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution effect after the US market opens on June 28, according to a preliminary list of additions posted June 4.

• Positive Preliminary Results from Delcath Systems’ FOCUS Trial Presented at the 2021 ASCO Annual Meeting

  6/7/2021

  As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for the Best Alternative Care Arm Company Q&A Webinar Today at 8:30am ET

• Delcath Systems to Present at LD Micro Virtual Investor Conference on June 10, 2021, at 2:30pm ET

  6/3/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management

• Delcath Systems to Present at Jefferies Virtual Healthcare Conference

  5/26/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at:

• Delcath Systems, Inc. Announces First Quarter 2021 Results

  5/11/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, reported business highlights and financial results for the first quarter ended March 31, 2021.

• Delcath Systems Schedules Conference Call to Report 2021 First Quarter Financial Results

  4/30/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2021. 

• Delcath Systems Announces Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

  4/30/2021

  Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually June 4-8, 2021,

• Delcath Systems, Inc. Announces Revised NICE Guidance for CHEMOSAT in the United KingdomRecommends Special Arrangement Designation Which Increases Reimbursement Options

  4/21/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the United Kingdom’s (UK) National Institute for Health and Care Excellence (NICE), through the Interventional Procedures Advisory Committee, has updated its guidance for the Delcath CHEMOSAT®

• Delcath Systems, Inc. Shares Additional Information Regarding FOCUS Trial Power Calculation20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% Threshold

  3/31/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, provided additional information regarding the power calculation for the Phase 3 FOCUS trial of HEPZATO KIT in patients with liver dominant metastatic ocular melanoma.

• Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular Melanoma

  3/31/2021

  - Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced positive top-line preliminary results from the company's Phase 3 FOCUS trial of HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system)

• Delcath Systems, Inc. Announces Fourth Quarter 2020 Results, Highlights Preliminary Positive FOCUS Trial Results; Conference Call Today at 8:00am Eastern Time

  3/31/2021

  Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December 31, 2020, and earlier today reported preliminary topline data. The company will host its quarterly call at 8:00am ET today, with a primary focus on discussing the preliminary top line data.

• Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial Results

  3/24/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time to discuss results for its fourth quarter ended December 31, 2020.

• Delcath Systems to Participate at Upcoming Virtual Investor Conferences - Mar 08, 2021

  3/8/2021

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced that management will participate at these upcoming virtual investor conferences

• Delcath Systems to Participate at Upcoming Virtual Investor Conferences

  2/11/2021

  Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:

• Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect Conference

  1/11/2021

  Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.

• Delcath Systems Announces Completion of Underwritten Public Offering

  12/11/2020

  Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of its common stock, including 219,004 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by D

• Delcath Systems Announces Pricing of Public Offering of Common Stock - Dec 09, 2020

  12/9/2020

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced the pricing of an underwritten public offering of 1,460,027 shares of its common stock at a public offering price of $13.25 per share.

• Kevin Muir Joins Delcath Systems, Inc. as VP, Commercial Operations

  12/7/2020

  Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced Kevin Muir has joined the company as Vice President of Commercial Operations.